ATE317381T1 - Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen - Google Patents

Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen

Info

Publication number
ATE317381T1
ATE317381T1 AT97910909T AT97910909T ATE317381T1 AT E317381 T1 ATE317381 T1 AT E317381T1 AT 97910909 T AT97910909 T AT 97910909T AT 97910909 T AT97910909 T AT 97910909T AT E317381 T1 ATE317381 T1 AT E317381T1
Authority
AT
Austria
Prior art keywords
interleukin
inhibitors
pct
asparagic
sulfonamide
Prior art date
Application number
AT97910909T
Other languages
English (en)
Inventor
Hamish John Allen
Kenneth Dale Brady
William Glen Harter
Elizabeth Ann Lunney
Mark Stephen Plummer
Tomi Sawyer
Aurash Shahripour
Nigel Walker
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE317381T1 publication Critical patent/ATE317381T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
AT97910909T 1996-10-11 1997-10-09 Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen ATE317381T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2832396P 1996-10-11 1996-10-11

Publications (1)

Publication Number Publication Date
ATE317381T1 true ATE317381T1 (de) 2006-02-15

Family

ID=21842812

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97910909T ATE317381T1 (de) 1996-10-11 1997-10-09 Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen

Country Status (14)

Country Link
US (1) US6083981A (de)
EP (1) EP0932600B1 (de)
JP (1) JP2001502330A (de)
KR (1) KR20000049050A (de)
AT (1) ATE317381T1 (de)
AU (1) AU742746B2 (de)
BR (1) BR9713314A (de)
CA (1) CA2268103A1 (de)
DE (1) DE69735230D1 (de)
IL (1) IL129124A0 (de)
NO (1) NO315042B1 (de)
NZ (1) NZ334887A (de)
PL (1) PL332704A1 (de)
WO (1) WO1998016504A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267853T3 (es) 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
JP2005500996A (ja) 2001-05-10 2005-01-13 アボット ゲーエムベーハー ウント カンパニー カーゲー アリールスルホンアミドエーテルおよびそれの使用方法
CN100556450C (zh) * 2001-05-16 2009-11-04 耶达研究发展有限公司 Il-18抑制剂在治疗或预防脓毒症中的应用
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
JP2007528405A (ja) * 2004-03-11 2007-10-11 イーラン ファーマスーティカルズ、インコーポレイテッド N−置換ベンゼンスルホンアミド
CA2566362C (en) 2004-05-15 2013-09-10 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
JPWO2005110450A1 (ja) * 2004-05-17 2008-03-21 学校法人慶應義塾 医薬組成物及び治療方法
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
KR20100072167A (ko) 2007-08-03 2010-06-30 사노피-아벤티스 카스파제 이미징 프로브
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティBrandeis University Ice阻害化合物およびその使用
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
EP2848696A1 (de) 2013-09-13 2015-03-18 Sanofi-Aventis Deutschland GmbH Caspase-1-Bildgebungssonden
WO2026082873A1 (en) 2024-10-17 2026-04-23 Institut National de la Santé et de la Recherche Médicale Use of caspase-1 inhibitors for treating ineffective erythropoiesis in patients suffering from sickle cell disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2071674C (en) * 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
GB9200420D0 (en) * 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
CA2186511C (en) * 1994-03-31 2009-02-10 Roland E. Dolle Pyrimidinyl derivatives as interleukin inhibitors
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme

Also Published As

Publication number Publication date
EP0932600B1 (de) 2006-02-08
NO315042B1 (no) 2003-06-30
EP0932600A2 (de) 1999-08-04
WO1998016504A3 (en) 1998-06-25
DE69735230D1 (de) 2006-04-20
AU4817297A (en) 1998-05-11
US6083981A (en) 2000-07-04
AU742746B2 (en) 2002-01-10
JP2001502330A (ja) 2001-02-20
NO991678L (no) 1999-04-12
BR9713314A (pt) 2000-01-25
PL332704A1 (en) 1999-09-27
WO1998016504A2 (en) 1998-04-23
KR20000049050A (ko) 2000-07-25
NZ334887A (en) 2000-09-29
NO991678D0 (no) 1999-04-09
IL129124A0 (en) 2000-02-17
CA2268103A1 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
NO991674D0 (no) Interleukin-1<Beta>omdannelsesenzym-inhibitor-sulfonamider
DE69635458T2 (de) Inhibitoren des interleukin-1-beta konvertierenden enzyms
BR9712530A (pt) Inibidores de ésteres de asparato de enzima de conversão de interleucina-1beta
PT966465E (pt) Inibidores do enzima imfdh
PT1049703E (pt) Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
EA200400648A1 (ru) N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
DE69735230D1 (de) Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen
EA200000871A1 (ru) Ингибиторы фосфолипазных ферментов
BG101130A (bg) Инхибитори на интерлевкин 1 бета-конвертиращ ензим
ID18143A (id) Penghambat metaloprotease amina siklik tersubstitusi
AP2001002217A0 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
EA200100992A1 (ru) Ингибиторы фермента impdh
DE69232929D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
BG101937A (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
AP0202538A0 (en) Inhibitors of interleukin -1b converting enzyme.
TNSN00250A1 (fr) Composes nouveaux inhibiteurs de pcp, procede pour leur preparation et compositions les contenant
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
BR9911010A (pt) Inibidores de sucinamida de enzima de conversão da interleucina-1beta
MXPA03010179A (es) Eteres de arilsulfonamida y metodos de uso de los mismos.
FI974444A0 (fi) N-hydroksiureayhdisteitä anti-inflammatorisina aineina
DK0751940T3 (da) Sesquiterpenderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties